focus -WSS

focus

author：entertainment 2025-09-28 00:53:32 - browse：34734

Blood samples — Marion Berard/AFP/GettyImages

With the advent of disease-modifying Alzheimer’s drugs, everyone in the world of Alzheimer’s diagnostics is bracing for the crush.

Based on their ability to slow cognitive decline, the Eisai/Biogen drug Leqembi won full approval from the FDA this month, and donanemab by Eli Lilly could be approved by year end. Clinicians now have to decide which patients are most suitable for treatment, which means better Alzheimer’s tests need to be developed.

“There’s going to be capacity issues because there’s just not enough neurologists in the world to treat this pool of patients with Alzheimer’s disease at the moment,” said Mark Stearman, a senior international product manager at Roche focusing on Alzheimer’s diagnostics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections
Next article： The FDA weighs the risks of candy

Wikipedia

WSS

Physician subsidies by hospitals soar in wake of No Surprises Act

For AI in health care standards, federal regulators join with industry group

Meta's Zuckerberg and Chan on track to put $50 billion into science

IVF doctors demand details after CooperSurgical lawsuit

Microsoft's Peter Lee: Generative AI could help doctors be more human

The pink breast cancer awareness ribbon needs a redesign

leisure time

focus

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Diversifying clinical trials isn't enough to close racial gaps: study

Medical records are filled with copy

Readout Newsletter: BridgeBio, Akero, and human embryo models

Wildfire smoke exposes gaps in outdoor worker protections

Paying for Covid pills will soon shift to insurers

BioMarin wins approval for gene therapy to treat hemophilia A

State of the Union pitch: Bigger Medicare drug price negotiations

Anesthesiologist group: stop taking Ozempic before surgery

Diversifying clinical trials isn't enough to close racial gaps: study

focus

Physician subsidies by hospitals soar in wake of No Surprises Act

Meta's Zuckerberg and Chan on track to put $50 billion into science

Senate panel to vote on hospitals, PBMs, prisoner care

Diversifying clinical trials isn't enough to close racial gaps: study

Paying for Covid pills will soon shift to insurers

Diversifying clinical trials isn't enough to close racial gaps: study

knowledge

Wikipedia

knowledge

knowledge